UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
July 18, 2006
Date of Report (Date of earliest event reported)
--------------------------------------------------------------------------------
ANTIGENICS INC.
(Exact name of registrant as specified in its charter)
--------------------------------------------------------------------------------
DELAWARE 000-29089 06-1562417
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
630 Fifth Avenue, Suite 2100
New York, NY 10111 10111
(Address of principal executive offices) (Zip Code)
212-994-8200
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers
On July 24, 2006, Antigenics Inc. announced that Peter Thornton,
Senior Vice-President and Chief Financial Officer as well as
principal financial officer and principal accounting officer
would be resigning in September. Effective upon his resignation,
Shalini Sharp will become Vice-President and Chief Financial
Officer as well as principal financial officer and Christine
Klaskin will become Vice-President Finance and principal
accounting officer. The full text of the press release issued in
connection with the announcement is being furnished as Exhibit
99.1 to this current report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is furnished herewith:
99.1 Press Release dated July 24, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANTIGENICS INC.
Date: July 24, 2006 By: /s/ Garo H. Armen
-----------------
Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description of Exhibit
----------- ----------------------
99.1 Press Release dated July 24, 2006